Welcome to our dedicated page for bpsr news (Ticker: bpsr), a resource for investors and traders seeking the latest updates and insights on bpsr stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect bpsr's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of bpsr's position in the market.
Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR) has announced that FINRA has approved its marketplace name change to Organicell Regenerative Medicine, Inc. and trading symbol change to OCEL. This change will take effect on November 8, 2021, with no action required from stockholders. The name change aims to reduce confusion in the market.
Organicell specializes in developing regenerative therapies using exosomes for treating degenerative diseases, focusing on innovation in biopharmaceuticals.
Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR) announced successful results from its expanded access clinical trial for ZofinTM, demonstrating both safety and efficacy in treating mild to moderate COVID-19. Key findings include a significant reduction in pulmonary opacities, a marked decrease in inflammatory biomarkers, and high patient recovery rates. The results will be submitted to the FDA for a Phase 2 trial amendment. The trial, conducted at United Memorial Medical Center in Houston, showed that 83% of patients had normal lung imaging post-treatment, highlighting ZofinTM as a potential effective treatment.
Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR) has launched its first autologous product, Patient Pure XTM (PPXTM), a biologic derived from a patient’s own peripheral blood. The product aims to harness nanoparticles from blood to promote regenerative effects, processed in the company’s cGMP compliant facility. The global autologous cell therapy market is projected to grow significantly, from USD 9.29 billion in 2019 to USD 42.68 billion by 2027, with a CAGR of 21.00%. Organicell plans to expand its autologous product line throughout 2021.
Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR) announced its presentation at the ISCT annual meeting from May 26-28, 2021. Their work, selected for an oral presentation, focuses on Zofin™ and its potential in treating COVID-19, showing decreased inflammatory biomarkers in severely ill patients. Zofin™, which contains over 300 growth factors, is currently in a phase I/II clinical trial to assess its safety and efficacy against COVID-19. The company aims to translate its findings into innovative treatments for degenerative diseases.
Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR) has entered an exclusive distribution agreement with Apex Services Pakistan to distribute ZofinTM for COVID-19 treatment in Pakistan. The agreement, which requires necessary regulatory approvals, will enable Apex Services to exclusively market ZofinTM if broader usage is permitted. The initial term is one year with potential renewal based on sales performance. CEO Albert Mitrani emphasized that this partnership enhances access to ZofinTM for COVID-19 patients in Pakistan and supports future clinical trials.
Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR) announced that its Zofin™ therapy has received approval from Pakistani regulators for compassionate use in a COVID-19 patient. The Drug Regulatory Authority of Pakistan authorized Zofin™ for a patient undergoing treatment in an intensive care unit. This approval allows for a broader trial involving up to 60 additional patients with moderate to severe COVID-19, with the company aiming to commence the trials soon. Zofin™ is a biologic therapy containing various growth factors and is undergoing a Phase I/II trial for safety and efficacy.
Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR) is pursuing an up-listing to NASDAQ Capital Market, aiming to enhance liquidity and visibility for shareholders. To qualify, the company must meet specific criteria, including $5 million in shareholder equity and a minimum share price of $4.00. This may necessitate raising more capital through offerings or conducting a reverse stock split. CEO Albert Mitrani emphasizes the strategic importance of this move for funding clinical trials. However, there are no guarantees that the company will meet the NASDAQ requirements or secure listing.
Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR) announced positive results from its initial trial of Zofin™ on COVID-19 patients in India. Ten hospitalized patients have recovered and were discharged after treatment at three hospitals. An expanded trial will include 65 additional patients. If successful, Organicell and CWI India will seek Emergency Use Approval from ICMR for Zofin™. The treatment aims to address the severe COVID-19 crisis in India, which is experiencing over 350,000 new infections daily.
Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR) has completed enrollment in its FDA-approved expanded access trial for Zofin, targeting COVID-19 patients. The trial is aimed at outpatient and inpatient individuals with mild to moderate COVID-19, at the United Memorial Medical Center in Houston, TX. Initial data analysis will commence in about 75 days, with trial completion expected within 90 days post the last patient dosing. Zofin, derived from perinatal sources, includes over 300 growth factors, and cytokines, and aims to introduce a novel therapy for COVID-19.
Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR) announced FDA approval for its Investigational New Drug (IND) application of Zofin™ to treat knee osteoarthritis. The clinical trial, starting in Q2, will be a double-blind, placebo-controlled phase I/II study focusing on Zofin's safety and efficacy for patients with this common degenerative disease, impacting over 32 million adults in the U.S. Zofin is a biologic therapy derived from perinatal sources, containing over 300 growth factors and unique microRNAs.
